A peritoneal dialysis solution prepared from a three-compartment bag: biological and clinical effects

Contrib Nephrol. 2001:(131):97-106. doi: 10.1159/000060067.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study

MeSH terms

  • Aged
  • Apoptosis / drug effects
  • Caspase 9
  • Caspases / analysis
  • Cells, Cultured
  • Dialysis Solutions / administration & dosage
  • Dialysis Solutions / adverse effects
  • Dialysis Solutions / chemistry
  • Dialysis Solutions / pharmacology*
  • Drug Packaging / instrumentation*
  • Drug Storage
  • Electrolytes / administration & dosage
  • Electrolytes / chemistry
  • Epithelium / chemistry
  • Epithelium / drug effects*
  • Equipment Design
  • Female
  • Glucose / administration & dosage
  • Glucose / adverse effects
  • Glucose / chemistry
  • Glycation End Products, Advanced / adverse effects
  • Glycation End Products, Advanced / chemistry
  • Glycation End Products, Advanced / pharmacology*
  • Glycosylation
  • Humans
  • In Situ Nick-End Labeling
  • Male
  • Membrane Proteins / chemistry
  • Membrane Proteins / drug effects
  • Middle Aged
  • Peritoneal Dialysis / adverse effects
  • Peritoneal Dialysis, Continuous Ambulatory* / adverse effects
  • Peritoneum / chemistry
  • Peritoneum / cytology
  • Peritoneum / drug effects*
  • Tumor Suppressor Protein p53 / analysis
  • Uremia / blood
  • Uremia / therapy*

Substances

  • Dialysis Solutions
  • Electrolytes
  • Glycation End Products, Advanced
  • Membrane Proteins
  • Tumor Suppressor Protein p53
  • CASP9 protein, human
  • Caspase 9
  • Caspases
  • Glucose